This article is more than 5 years old. Information may no longer be current.
October's top dermatology reads include sunscreen, psoriasis studies
Click Here to Manage Email Alerts
Research finding that women who applied broad-spectrum photostable sunscreen to their face daily for a year showed improvement in the signs of existing photodamaged skin was among the most-read articles in October on Healio.com/Dermatology.
Other widely read articles included study findings that Xeljanz improved pruritus and quality of life up to 1 year in patients with psoriasis and that patients with moderate-to-severe plaque psoriasis maintained skin clearance after 4 years of treatment with Cosentyx:
Daily use of broad spectrum sunscreen may reverse signs of photodamage
Women who applied broad-spectrum photostable sunscreen to their face daily for a year showed improvement in the signs of existing photodamaged skin, according to study results published in Dermatologic Surgery.
Researchers studied 33 women aged 40 to 55 years with Fitzpatrick skin types 1 to 3, mild-to-moderate photodamage and in general good health. Read more
Melanoma-associated leukoderma may be misdiagnosed as vitiligo
Experts frequently misdiagnosed melanoma-associated leukoderma as vitiligo in a blinded assessment, according to study results published in the Journal of the American Academy of Dermatology.
Researchers conducted a study using clinical photographs of 11 patients with melanoma-associated leukoderma (MAL) and 33 patients with vitiligo at The Netherlands Institute for Pigment Disorders in Amsterdam. Read more
Xeljanz improved pruritus, QoL up to 1 year in patients with psoriasis
Patients with moderate-to-severe psoriasis who were treated with Xeljanz saw improvements in health-related quality of life over 52 weeks, with rapid improvement in pruritus, according to research published in the Journal of the American Academy of Dermatology.
“Plaque psoriasis is a chronic disease therefore providing long-term improvement in [health-related quality of life] is a key goal of therapy,” Steven R. Feldman, MD, PhD, of Wake Forest School of Medicine, Winston-Salem, North Carolina, and colleagues wrote. Read more
Dupixent shows efficacy in treating atopic dermatitis
Adults with atopic dermatitis who were treated with Dupixent in two identical phase 3 trials experienced improvement in severity of disease and in symptoms including pruritus, anxiety and depression, according to study results published in The New England Journal of Medicine.
“These results support a growing body of evident for Dupixent as a potential new treatment option for patients with moderate-to-severe atopic dermatitis who are struggling to control their disease,” researcher Eric L. Simpson, MD, MCR, Oregon Health and Science University, stated in a press release. Read more
Cosentyx demonstrates efficacy in skin clearance for psoriasis over 4 years
Novartis has announced that patients with moderate-to-severe plaque psoriasis maintained skin clearance after 4 years of treatment with Cosentyx, according to research presented at the European Academy of Dermatology and Venereology Congress in Vienna.
“[Study results] show that Cosentyx [secukinumab] keeps working year-on-year, maintaining high levels of skin clearance with a favorable safety profile,” Vasant Narashimhan, global head, Drug Development and chief medical officer of Novartis, stated in a press release. Read more